Clinical TrialsMino-Lok has the potential to salvage the catheter with a 100% salvage rate in Phase 2b.
Regulatory ApprovalThe FDA provided clear, constructive, and actionable guidance for a future New Drug Application submission for Mino-Lok, supporting its pathway to regulatory approval.
ReimbursementCitius has achieved a critical milestone in future Lymphir commercialization and patient support with the assignment of a unique, permanent HCPCS J-code by the CMS.